ARS Pharmaceuticals (SPRY) Receivables - Other (2021 - 2025)
Historic Receivables - Other for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $4.3 million.
- ARS Pharmaceuticals' Receivables - Other rose 270855.26% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 270855.26%. This contributed to the annual value of $1.2 million for FY2024, which is 8895.71% up from last year.
- Per ARS Pharmaceuticals' latest filing, its Receivables - Other stood at $4.3 million for Q3 2025, which was up 270855.26% from $2.0 million recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Receivables - Other ranged from a high of $4.3 million in Q3 2025 and a low of $122000.0 during Q2 2024
- Its 5-year average for Receivables - Other is $841000.0, with a median of $307000.0 in 2023.
- Per our database at Business Quant, ARS Pharmaceuticals' Receivables - Other plummeted by 6504.3% in 2024 and then skyrocketed by 270855.26% in 2025.
- Quarter analysis of 5 years shows ARS Pharmaceuticals' Receivables - Other stood at $159000.0 in 2021, then surged by 33.96% to $213000.0 in 2022, then soared by 206.1% to $652000.0 in 2023, then surged by 88.96% to $1.2 million in 2024, then surged by 246.51% to $4.3 million in 2025.
- Its Receivables - Other stands at $4.3 million for Q3 2025, versus $2.0 million for Q2 2025 and $963000.0 for Q1 2025.